Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 4, 2013, Pages 552-557

  Leal, Pamela ^a   Garćia, Patricia ^a,c   Sandoval, Alejandra ^a   Letelier, Pablo ^a   Brebi, Priscilla ^a   Ili, Carmen ^a   Álvarez, Héctor ^b   Tapia, Oscar ^a   Roa, Juan C ^a,c  

^a UNIVERSIDAD DE LA FRONTERA   (Chile)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; CANCER STAGING; CHILE; CHOLECYSTECTOMY; CHOLECYSTITIS; CHRONIC DISEASE; FEMALE; GALLBLADDER TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METAPLASIA; METHODOLOGY; MIDDLE AGED; MORTALITY; PHOSPHORYLATION; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TISSUE MICROARRAY;

ADENOCARCINOMA; AGED; CHILE; CHOLECYSTECTOMY; CHOLECYSTITIS; CHRONIC DISEASE; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METAPLASIA; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84876543858     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0032-OA     Document Type: Article

References (58)

1. Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E, Salemis NS. Gallbladder cancer. Am J Surg. 2008;196(2):252-264. (Pubitemid 351970506)
2. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118(7):1591-1602. (Pubitemid 43376420)
3. Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349- 364. (Pubitemid 34232782)
4. Goldin RD, Roa JC. Gallbladder cancer: a morphological and molecular update. Histopathology. 2009;55(2):218-229.
5. Ministerio de Salud, MINSAL. Gobierno de Chile. Estadisticas de Salud. 2009.
6. Pandey M. Risk factors for gallbladder cancer: a reappraisal. Eur J Cancer Prev. 2003;12(1):15-24. (Pubitemid 36233018)
7. Pandey M, Shukla VK. Lifestyle, parity, menstrual and reproductive factors and risk of gallbladder cancer. Eur J Cancer Prev. 2003;12(4):269-272. (Pubitemid 36994080)
8. Roa I, Araya JC, Villaseca M, et al. Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression. Gastroenterology. 1996;111(1):232-236. (Pubitemid 26226904)
9. Bartlett DL. Gallbladder cancer. Semin Surg Oncol. 2000;19(2):145-155.
10. Wistuba, II, Miquel JF, Gazdar AF, Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol. 1999;30(1):21-25. (Pubitemid 29037389)
11. Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist.15(2):168-181.
12. de Aretxabala X, Roa I, Hepp J, et al. Early gallbladder cancer: is further treatment necessary? J Surg Oncol. 2009;100(7):589-593.
13. Roa I, de Aretxabala X, Araya JC, et al. Morphological prognostic elements in gallbladder cancer [in Spanish]. Rev Med Chil. 2002;130(4):387-395.
14. Shih SP, Schulick RD, Cameron JL, et al. Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg. 2007;245(6):893-901. (Pubitemid 46809291)
15. de Aretxabala XA, Roa IS, Burgos LA, Araya JC, Villaseca MA, Silva JA. Curative resection in potentially resectable tumours of the gallbladder. Eur J Surg. 1997;163(6):419-426. (Pubitemid 27278719)
16. de Aretxabala XA, Roa IS, Mora JP, et al. Laparoscopic cholecystectomy: its effect on the prognosis of patients with gallbladder cancer. World J Surg. 2004; 28(6):544-547. (Pubitemid 38802788)
17. Parvez T, Parvez B, Alharbi TM. Advanced carcinoma gallbladder. J Coll Physicians Surg Pak. 2007;17(3):175-179.
18. Abahssain H, Afchain P, Melas N, et al. Chemotherapy in gallbladder carcinoma [in French]. Presse Med. 2010;39(12):1238-1245.
19. de Aretxabala X, Losada H, Mora J, et al. Neoadjuvant chemoradiotherapy in gallbladder cancer [in Spanish]. Rev Med Chil. 2004;132(1):51-57.
20. Rudi J. Chemotherapy with gemcitabine in patients with gall-bladder carcinoma. Ann Oncol. 2002;13(5):807. (Pubitemid 34567391)
21. Thomas MB. Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. Crit Rev Oncol Hematol. 2007;61(1):44-51. (Pubitemid 44880150)
22. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des. 2010;16(1): 34-44.
23. Ciuffreda L, Di Sanza C, Incani UC, Milella M. The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets. 2010;10(5):484-495.
24. Chen M, Cassidy A, Gu J, et al. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis. 2009;30(12):2047-2052.
25. Dai B, Kong YY, Ye DW, Ma CG, Zhou X, Yao XD. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int. 2009;104(7): 1009-1016.
26. Li XY, Zhang LQ, Zhang XG, et al. Association between AKT/mTOR signalling pathway and malignancy grade of human gliomas. J Neurooncol. 2011;103(3):453-458.
27. Zhou H, Luo Y, Huang S. Updates of mTOR inhibitors. Anticancer Agents Med Chem. 2010;10(7):571-581.
28. Lane HA, Wood JM, McSheehy PM, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 2009;15(5):1612-1622.
29. Mabuchi S, Altomare DA, Connolly DC, et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 2007;67(6):2408-2413. (Pubitemid 46548923)
30. Mabuchi S, Kawase C, Altomare DA, et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res. 2009;15(17):5404-5413.
31. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-1474.
32. Xiao L, Wang YC, Li WS, Du Y. The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res. 2009;28:152.
33. Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther. 2003;2(4 suppl 1):S169-S177.
34. Yang Q, Guan KL. Expanding mTOR signaling. Cell Res. 2007;17(8):666- 681. (Pubitemid 47255937)
35. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6(9):729-734. (Pubitemid 44286004)
36. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006;6(3):184-192. (Pubitemid 43292562)
37. Baba Y, Nosho K, Shima K, et al. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer. 2011;117(7):1399-1408.
38. Michelucci A, Di Cristofano C, Lami A, et al. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol. 2009; 18(4):200-205.
39. Kinross KM, Montgomery KG, Kleinschmidt M, et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest. 2012;122(2):553-557.
40. Hartmann C, Bartels G, Gehlhaar C, Holtkamp N, von Deimling A. PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol. 2005;109(6): 639-642. (Pubitemid 40974153)
41. Corso G, Velho S, Paredes J, et al. Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer. 2011;47(3):443-451.
42. Chaft JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther. 2012;11(2):485-491.
43. Riener MO, Bawohl M, Clavien PA, Jochum W. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer. 2008; 47(5):363-367. (Pubitemid 351451790)
44. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005;17(6):596-603. (Pubitemid 41540408)
45. Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs. 2008;17(11):1717-1734.
46. Herberger B, Puhalla H, Lehnert M, et al. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res. 2007;13(16):4795-4799. (Pubitemid 47294786)
47. Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol. 2010;27(2): 255-261.
48. Mukhopadhyay S, Landas SK. Putative precursors of gallbladder dysplasia: a review of 400 routinely resected specimens. Arch Pathol Lab Med. 2005; 129(3):386-390. (Pubitemid 40343996)
49. Barcia JJ. Histologic analysis of chronic inflammatory patterns in the gallbladder: diagnostic criteria for reporting cholecystitis. Ann Diagn Pathol. 2003;7(3):147-153. (Pubitemid 36714289)
50. Duarte I, Llanos O, Domke H, Harz C, Valdivieso V. Metaplasia and precursor lesions of gallbladder carcinoma: frequency, distribution, and probability of detection in routine histologic samples. Cancer. 1993;72(6): 1878-1884. (Pubitemid 23262115)
51. Feng W, Brown RE, Trung CD, et al. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci. 2008;38(3):195-209.
52. Kim Y, Jeong H, Kim A, Kim HK, Shin BK. Frequent activation of mammalian target of rapamycin in primary lung adenocarcinoma and preinvasive lesion. Basic Appl Pathol. 2011;4(3):78-85.
53. An JY, Kim KM, Choi MG, et al. Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer. Int J Cancer. 2010;126(12):2904-2913.
54. de Aretxabala X, Roa I, Mora J, et al. Management of gallbladder cancer with invasion of the muscular layer [in Spanish]. Rev Med Chil. 2004;132(2):183- 188.
55. van der Heijden MS, Bernards R. Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res. 2010;16(12):3094-3099.
56. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol. 2003;3(4):371-377. (Pubitemid 36908940)
57. Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol. 2008;1(1-4):27-36.
58. Rizzieri DA, Feldman E, Dipersio JF, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008;14(9):2756-2762.